Despite data indicating that patients suffering from metastatic colorectal cancer with wild-type KRAS status might benefit from first-line therapy with panitumumab, several unresolved issues make it difficult to judge its final clinical value. Phase III trials demonstrated superiority of adding panitumumab to standard of care vs. standard of care alone for the surrogate endpoint progression free survival. Therefore, regulatory authorities approved panitumumab for the 1st-line treatment of mCRC linked to the condition of further assessments incorporating patient relevant outcomes such as quality of life and overall survival.